Advisory Board

 
  • G. Russell Bell
    Chief Scientific Officer Emeritus
    Beckman Coulter, Inc.
    President, Beckman Coulter Foundation
     

    G. Russell “Russ” Bell, 64, retired from Beckman Coulter, having served as Senior Vice President and Chief Scientific Officer. He joined the company as President and CEO of Hybritech Incorporated, the former subsidiary of Eli Lilly and Company, acquired by Beckman Instruments, Inc. in January 1996. Previously Dr. Bell held executive positions with du Pont and was President of Jacksonville Reference Laboratories. Throughout his career Dr. Bell spearheaded the development of many diagnostic products in cancer, men’s and women’s health and cardiovascular disease. He is active volunteering with Cancer Treatment Center at St. Peter’s Hospital, Helena, Montana.
     
    Born in Atlanta, Ga., Dr. Bell received his Bachelor of Science degree in Applied Biology (1969) and his Master of Science (1970) from Georgia Tech and his doctorate in Biochemistry in 1973 from the University of Georgia where he was a National Science Foundation Fellow. Dr. Bell is a member of Phi Kappa Phi, scholastic honor society. He has served on the Advisory Boards of the Petit Institute of Bioscience and Bioengineering at Georgia Tech, the Wallace G. Coulter Foundation and the Betty Irene Moore School of Nursing at UC Davis. He has been President of the Beckman Coulter Foundation since its formation in September 2007.
     
    Dr. Bell and his wife Sharon reside in Clancy, Montana.

  • Tom Callaway
    President
    Life Science Partner, Inc.

    Dr. Thomas H. Callaway is Chief Executive Officer and serves on the board of AerovectRx, an aerosol vaccine delivery company which is commercializing technology developed at the Centers for Disease Control and Prevention. Tom is the Founder and President of Life Science Partner, an executive search firm focused exclusively on recruiting scientific and managerial leaders for the life sciences industry including companies developing medical devices, diagnostics, biopharmaceuticals and convergent technologies. Tom is also a founding Partner of an early stage seed fund, Georgia Venture Partners. Georgia Venture Partners was established in 2004 to make seed and early-stage investments in life sciences enterprises related to Georgia. As an investor, he takes an active role in the management of the portfolio start-ups. He is a former Partner with Fuqua Ventures (a life science and technology venture capital fund) and two leading recruiting firms Russell Reynolds and Korn/Ferry International. Active in the investing community of the Southeast, Tom is the Vice Chairman, Georgia BIO, the regions largest life science organization, and serves on the boards of the Atlanta Venture Forum and Southeast BIO. Before moving to Atlanta, Tom held the position of Director, Commercial Development for SyStemix. There he was responsible for business development and marketing for the firm's proprietary stem cell technology for bone marrow rescue of patients following high dose chemotherapy. He began his biotechnology career at Roche Diagnostics and Roche Molecular Systems. During his tenure at Roche, he developed and executed a global marketing plan for polymerase chain reaction (PCR) diagnostics technology, a Noble-prize winning solution for sleuthing out specific sequences of DNA and commercializing the tools to map the human genome. Tom earned a medical degree from Vanderbilt University School of Medicine. He holds an MBA and undergraduate degree from Duke University. He can be reached at tom@lifesciencepartner.com.

  • Art Coury
    Principal
    Coury Consulting Services

    Art Coury holds a B.S. degree in chemistry from the University of Delaware (1962), a Ph.D. in organic chemistry (1965) and an M.B.A. (1980) from the University of Minnesota. His industrial career includes positions as: Senior Research Chemist at General Mills, Inc. (1965-1976), Director, Polymer Technology and Research Fellow at Medtronic, Inc. (1976-1993), Vice President, Research and Chief Scientific Officer at Focal, Inc. (1993-2000), and Vice President, Biomaterials Research at Genzyme Corporation (2000-June, 2008). He currently is a consultant. His career focus has been polymeric biomaterials for medical products such as implantable electronic devices, hydrogel-based devices and drug delivery systems. He holds over fifty distinct patents and has published and presented widely in his field. His teaching positions have included adjunct or affiliate appointments at the University of Minnesota, the Harvard-MIT Graduate Program in Health Sciences and Technology and the University of Trento, Italy. His professional service has included: Chair, Minnesota Section, American Chemical Society (1989-1990); President, Society for Biomaterials, USA (1999-2000); President, American Institute for Medical and Biological Engineering (2003-2004) and membership on several university, society and corporate advisory boards. His recent recognitions have included the delivery of distinguished lectureships, receipt of the 2007 Innovation and Technology Development Award of the Society for Biomaterials, being named as one of "100 Notable People in the Medical Device Industry" by MD&DI magazine, 2008, induction into the National Academy of Engineering, USA, 2009 and induction on the University of Delaware "Wall of Fame," 2010.

  • David Dodd
    President, CEO & Managing Director
    Aeterna Zentaris

    Prior to forming RiversEdge BioVentures LLC, Mr. Dodd achieved a highly distinguished career, serving in executive positions in several major pharmaceutical and life sciences companies. Recently, Mr. Dodd served as President, CEO and Chairman of BioReliance Corporation, as an equity partner with Avista Capital Partners in establishing that organization as a stand-alone company following its purchase from Invitrogen Corporation (now, Life Technology, Inc.). In addition, Mr. Dodd served as the non-executive Chairman of Stem Cell Sciences Plc. (LSE:AIM STEM; ASX: STC), leading a strategic transformation and eventual sale of that company to Stem Cells Inc. in April, 2009. Mr. Dodd also served on the Board of Stheno Corporation, a private life sciences technology company. From June 2000 to July 2006, Mr. Dodd served as President, CEO and Director of Serologicals Corporation (NASDAQ: SERO), until the sale of Serologicals to Millipore Corporation (NYSE: MIL) in July, 2006. From August 1995 until June 2000, he served as President and Chief Executive Officer of Solvay Pharmaceuticals, Inc., and as a member of the Management Board for the Pharmaceutical Sector for Solvay S.A. Mr. Dodd also served as Chairman of the Board of Unimed Pharmaceuticals, Inc., a subsidiary of Solvay Pharmaceuticals. Prior to joining Solvay, he served in a number of management and executive positions with major life science corporations, including Wyeth, Bristol-Myers Squibb, and Abbott Laboratories. Mr. Dodd holds a Bachelor of Science and Master of Science from Georgia State University and completed the Harvard Business School Advanced Management Program.

  • Goodman Espy, III
    President
    OB-Gyn Associates

    Goodman B. "G.B." Espy received his bachelor's degree in Mechanical Engineering from Georgia Tech in 1957. He is the only known co-op student to have been elected to both ODK and the ANAK Society while at Georgia Tech. After graduation, he taught math as a graduate assistant and worked at the Georgia Tech Research Station on a number of medical projects before entering Tulane Medical School in 1958. In 1962 he received his M.D. degree, which was followed by four years of OB-GYN residency training at Tulane. Dr. Espy then entered the U.S. Army.

    In 1967, he founded OB-GYN Associates in Marietta, Georgia. He has delivered more than 12,000 babies in his career, and is credited with having delivered more babies than any other physician in Georgia. In 1993, he co-authored a new surgical approach for laparoscopic hysterectomies, which was reported in several medical publications. Overall, Dr. Espy has performed more than 10,000 surgical procedures.

    During the Kosovo War, in 1999, Dr. Espy went to refugee camps in Albania, and has since been very active in obtaining medical equipment for Albanians in an effort to upgrade what he calls "a deplorable example of the medical environment in which those less fortunate than we live." Under his leadership, his medical practice has funded more than thirty scholarships during the last twenty-five years, for students in need of an education in Europe and the United States.

    Dr. Espy served on the Georgia Tech Advisory Board from 1978 to 1986, and from 1988 until 1998, he was a member of the Woodruff School of Mechanical Engineering's Advisory Board. Since 1995, he has served on the External Advisory Board for the Institute of Bioengineering and Biosciences at Georgia Tech. In 2001, Dr. Espy was the recipient of the Beta Theta Pi National Leadership and Service Award. In 2002, he was given a Community Service Award by Channel 11, and in 2003 he received the Dr. Jack A. Raines Humanitarian Award from the Medical Association of Georgia. That award was given for "outstanding humanitarian contributions to his fellow man, community, country, and world community beyond the practice of medicine." He is on the board of directors of several organizations.

    Dr. Espy has a special interest in running, having run more than sixty marathons, including the last twenty-five New York Marathons.

  • Patrick Frias
    Chief Operating Officer
    Children's Healthcare of Atlanta

    Patrick Frias, M.D., is Chief Operating Officer of Children’s Healthcare of Atlanta. As COO, Frias oversees operations of all three Children’s hospitals and 25 neighborhood locations, including Marcus Autism Center. He is responsible for all physicians employed or managed by Children’s, which includes more than 350 physicians and 500 nursing staff, and represents more than 30 pediatric specialties ranging from primary care to the most highly specialized pediatric services. In addition to overseeing the clinical performance and management of physicians, Dr. Frias is responsible for working with Children’s academic partners in the development and execution of the organization’s academic mission. Dr. Frias is an accomplished, Board-certified cardiologist who maintains a practice within Sibley Heart Center Cardiology and is an associate professor of pediatrics at the Emory School of Medicine. He is a Fellow, American College of Cardiology, Fellow, American Academy of Pediatrics and Member, American College of Physician Executives. Prior to his role as Chief of the Children’s Physician Group, he served as Director of Outpatient Services for Sibley since 2005, and joined the Children’s professional staff in 2000. Dr. Frias holds a bachelor’s degree in Theology from Creighton University, and completed medical school at the University of Nebraska College of Medicine. He completed his pediatric residency at Duke University Medical Center before completing his pediatric cardiology and electrophysiology fellowships at Vanderbilt University Medical Center. Dr. Frias and his wife have a daughter and three sons.

  • Chris Gemmiti
    Business Development Lead
    Wyss Institute for Biologically Inspired Engineering

    Chris is the Business Development Lead at the Wyss Institute for Biologically Inspired Engineering at Harvard University. With a focus in regenerative medicine, he guides translation strategy and technology development as well as strategic partnering and company formation. He has 18 years experience in regenerative medicine, through various roles in academia and industry. Most recently, he founded Ridgewood Consulting LLC, a consulting firm dedicated to commercialization of biologic therapeutics. Previously, Chris was the Product Director at Organogenesis Inc where he was responsible for the launch of a new living cellular sheet, GINTUIT™.  GINTUIT™ marked the first-ever approval (2012) of a manufactured allogeneic cell product via the Center for Biologics Evaluation and Research (CBER) arm of the FDA. He maintains leadership positions with the Tissue Engineering Regenerative Medicine Interational Society (TERMIS) and Alliance for Regenerative Medicine (ARM). Chris holds a BS in Biomedical Engineering from The Johns Hopkins University and PhD in Biomedical Engineering jointly conferred by the Georgia Institute of Technology’s College of Engineering and Emory University’s School of Medicine. 

  • Steven Goldstein
    Henry Ruppenthal Family Professor of Orthopaedic Surgery and Bioengineering
    Associate Chair for Research in the Department of Orthopaedic Surgery
    University of Michigan

    Dr. Goldstein completed his undergraduate education at Tufts University, receiving a B.S. Degree in Mechanical Engineering in 1976. He subsequently entered the University of Michigan and was awarded the M.S. degree in Bioengineering in 1977 and Ph.D. in Bioengineering in 1981. He joined the faculty at the University of Michigan as a Research Investigator in the Section of Orthopaedic Surgery, Department of Surgery in 1981 and became an Assistant Professor of Surgery in 1983. He has risen through the academic ranks and currently is the Henry Ruppenthal Family Professor of Orthopaedic Surgery and Bioengineering and Associate Chair for Research in the Department of Orthopaedic Surgery. He also holds joint appointment as a Professor of both Mechanical Engineering and Biomedical Engineering. Dr. Goldstein's research is in the area of musculoskeletal science and focuses on connective tissue diseases, their prevention or treatment. His large and diverse research program includes studies ranging from fracture repair and reconstructive surgery, to investigating the mechanisms associated with inherited or degenerative connective tissue fragility to the development of strategies for tissue regeneration. His primary interests relate to the investigation of the effects of metabolic or mechanical influences on bone adaptation and tissue regeneration. Some of the findings have led to the development of a variety of implants and instruments, gene-based therapeutics for wound repair and novel diagnostic technology for tissue degradation. Dr. Goldstein's research is primarily supported by grants from the National Institutes of Health as well as numerous foundations, other federal agencies and corporate sponsors. He has published over 180 peer reviewed papers and has been invited to present his work at numerous national and international symposia. Dr. Goldstein has received numerous awards for his research, including: the 1988 Nicholas Andre Award from the Association of Bone and Joint Surgeons, the 1989 Kappa Delta Award for Excellence in Orthopaedic Research, the 1987 YC Fung young investigator award and the 2005 Lissner Medal for career achievements from the American Society of Mechanical Engineering and the 2003 Marshall Urist Award for Excellence in Tissue Regeneration Research from the Orthopaedic Research Society. He currently serves on the editorial boards of five journals and is an Associate Editor of the journal Bone. He has served as the Chair of the Orthopaedics and Musculoskeletal Science Study Section of the National Institutes of Health and holds or has held numerous leadership positions in national societies, including President of the Orthopaedic Research Society, Chair of the United States National Committee on Biomechanics, Chair-elect of the College of Fellows of the Association Institute of Medical and Biological Engineering and a board member for the Biomedical Engineering Society and The Tissue Engineering and Regenerative Medicine Society International. In 2005, Dr. Goldstein was elected a member of the National Academy of Engineering Dr. Goldstein has continuously been a very active participant in the Medical School and University community through many administrative positions and committee memberships. Perhaps most importantly, he served as the Assistant Dean (1993-1998) and then the Associate Dean for Research and Graduate Studies (1999-2004) in the Medical School.

  • Linda Griffith
    School of Engineering Teaching Innovation Professor of Biological and Mechanical Engineering
    Massachusetts Institute of Technology
    Director, Center for Gynepathology Research

     Linda G. Griffith, PhD, is the School of Engineering Teaching Innovation Professor of Biological and Mechanical Engineering and MacVicar Fellow at MIT, where she directs the Center for Gynepathology Research and the DARPA/NIH-funded Human Physiome on a Chip Program. Dr. Griffith received a Bachelor's Degree from Georgia Tech and a PhD degree from the University of California at Berkeley, both in chemical engineering. Dr. Griffith’s research is in the field of regenerative medicine and tissue engineering. Her laboratory, in collaboration with J. Upton and C. Vacanti, was the first to combine a degradable scaffold with donor cells to create tissue-engineered cartilage in the shape of a human ear. The 3D Printing Process she co-invented for creation of complex scaffolds is used for manufacture of FDA-approved scaffolds for bone regeneration. She is also a pioneer in devising ways to control nano-scale stimulation of cells by molecular cues, and in creation of 3D tissue models for drug development. Her work has been featured on television documentary shows including Scientific American Frontiers. She is a member of the National Academy of Engineering and the recipient of a MacArthur Foundation Fellowship, the Popular Science Brilliant 10 Award, NSF Presidential Young Investigator Award, the MIT Class of 1960 Teaching Innovation Award, Radcliffe Fellow and several awards from professional societies. She has served as a member of the Advisory Councils for the National Institute for Dental and Craniofacial Research and the National Institute of Arthritis, Musculoskeletal and Skin Diseases at NIH. As chair of the Undergraduate Curriculum Committee for Biological Engineering at MIT, she led development of the new Biological Engineering SB degree program, which was approved in 2005 as MIT’s first new undergraduate major in 39 years.

  • Anjali Kumar
    Due Diligence Lead, Corporate Development
    Shire Pharmaceuticals

    Anjali has had nearly 20 years of experience with increasing responsibility in the biopharmaceutical industry is currently the Due Diligence Lead, Corporate Development for Shire Pharmaceuticals. She previously served as the Vice President, Nonclinical R&D and Scientific Affairs at Flexion Therapeutics, Inc. She has a strong scientific background and Drug Discovery and Development experience gained in large pharmaceutical and small biotech company environments. She has experience advancing several small molecules and proteins into initial clinical development and continuing to support them through later stages of development and eventual regulatory approval. Anjail has worked in the area of inflammation in musculoskeletal, respiratory and cardiovascular diseases. She was previously Vice President of R&D at Clinquest, Inc. where she led the strategic drug development consulting team that worked on multiple programs in both the US and in Europe. Prior to that, she was Senior Director, Pharmacology at Critical Therapeutics, Inc. and Principal Scientist and Project Leader at Wyeth Research/Genetics Institute. She received her postdoctoral training at Pharmacia and Upjohn, Inc. She holds a PhD in Bioengineering from Georgia Institute of Technology and a Bachelor’s degree in Chemical Engineering from the Indian Institute of Technology.

  • Bruce Lavin
    Vice President, Medical Affairs, North America
    UCB Inc.

    Dr. Bruce Lavin is Vice President – Medical Affairs, North America and is responsible for leading and managing strategy for medical affairs issues and providing leadership, mentoring, supervision and oversight of the medical department. Dr. Lavin represents UCB’s medical and scientific interests in internal and external forums, while developing and supporting Phase IIIb and Phase IV Studies. Dr. Lavin is also a member of the U.S. Leadership Team. Dr. Lavin has 25 years of clinical experience and more than 15 years of industry experience, leading Medical Affairs and Clinical Development programs and divisions for major pharmaceutical companies in the areas of Immunology, Virology and Anti-infectives. Most recently, Dr. Lavin was the Vice President and Therapeutic Head for Bristol-Myers Squibb where he led the U.S. clinical and launch preparations for anti-virals in HIV, HCV, Rheumatology and Transplant. Prior to Bristol-Myers Squibb he held senior medical roles for both Novartis and Sanofi-Aventis in the areas of Infectious disease, Immunology, Transplantation, Virology and the Central Nervous System. Additionally, Dr. Lavin has a vast military career, currently serving as a Medical Doctor for the U.S. Navy Reserve. From 2009-2010, he provided medical care and support in a combat area during Operation Iraqi Freedom. Dr. Lavin holds a bachelor’s degree from the University of California Irvine and a master’s of Public Health from the University of California, Los Angeles. He received his medical degree from the F. Herbert School of Medicine at Uniformed Services University of the Health Sciences in Bethesda, Maryland.

  • Anthony Lee
    President
    Eyegenix

    Mr. Lee has over 18 years of experience in the medical device business. He is currently the President of Eyegenix LLC, a venture backed start-up developing a biosynthetic cornea for the treatment of corneal blindness.  In 2011, Eyegenix and sister company Skai Ventures were awarded the statewide winner of the APEC 2011 Business Innovation Showcase.  Prior to Eyegenix, Mr. Lee led the research and development team at Coalescent Surgical, Inc., a venture funded medical device startup focused on minimally invasive cardiovascular bypass and valve fixation.  Coalescent Surgical was acquired by Medtronic Inc in 2004.  Prior to his work at Coalescent, Mr. Lee led R&D efforts at two venture financed companies: Vivant Medical which was acquired by Valley Lab/Tyco, and AneuRx, which was acquired by Medtronic Inc. Mr. Lee is a registered Professional Engineer in the state of CA.  He holds numerous US and international patents with several pending. Mr Lee received his BME and MSME from Georgia Tech in 1993 and 1995, respectively.   He currently splits his time between San Francisco, CA and Honolulu, HI.

  • Kevin Maher
    Director, Pediatric Cardiac Nanomedicine
    Associate Director, Atlanta Pediatric Device Consortium
    Emory University School of Medicine

     Dr Kevin Maher graduated from the University of Maryland School of Medicine in 1991.  He completed a residency and chief residency in Pediatrics at Maryland and then went on the University of Michigan for a Fellowship in Pediatric Cardiology.  He completed further subspecialty training in cardiac intensive care and interventional catheterization at Thomas Jefferson University/DuPont Children’s Hospital.  In 2004 Dr Maher joined the Pediatric Cardiology group at Children’s Healthcare of Atlanta, Emory University School of Medicine.  His primary clinical responsibilities are in the pediatric cardiac intensive care unit at Children’s.  This unit cares for children from newborns through age 21 years and involves the pre and postoperative management of critical heart disease, including children with ventricular assist devices, extracorporeal support (ECMO) and cardiac transplantation.   A significant amount of time is devoted to teaching and research.  Dr Maher’s research activities include neonatal CPR,  cardiac biomarkers in children, development of novel therapies for congenital heart disease, and device development efforts.  In an attempt to find new treatments for cardiomyopathy, he brought together researchers at CHOA, Emory and Georgia Tech, developing the first Pediatric Nanomedicine Center in the country.  Dr Maher works to develop collaborations with Georgia Tech, aiming to bring engineers into the field of pediatric research and development.  To this end he is the director of Pediatric Cardiac Nanomedicine, the co-director of the Center for Pediatric Innovation and the co-director of the Atlanta Pediatric Device Consortium.

  • Robert (Bob) McNally
    President and CEO
    GeoVax Labs, Inc.

    Bob McNally became President and CEO of GeoVax Labs, Inc., in April 2008, after serving on its Board of Directors since 2006. He was previously Co-Founder and CEO of Cell Dynamics LLC. Cell Dynamics specialized in the recovery and GMP processing of human organs and tissues used for biotech and cellular medical therapies. During the period 1984 to 1998, Dr. McNally was Co-Founder and Sr. Vice President of Clinical Research for CryoLife, Inc., the market leader in transplantable human tissues including cryopreserved heart valves, veins, ligaments and tendons of the knee as well as a manufacturer of protein-derived surgical adhesives. Dr. McNally led and helped launch the company from startup through going public on the NASDAQ and NYSE. Dr. McNally received a Bachelor of Electrical Engineering (B.E.E.) degree from Villanova University, and has a Ph.D. in Biomedical Engineering from the University of Pennsylvania. He has authored numerous patents and publications in the field of transplantable tissues and is a frequent speaker for business development in Georgia and student groups. Currently, Dr. McNally serves as a member of the advisory boards of the Petit Institute for Bioengineering and Dupree College of Management at the Georgia Institute of Technology. He is an elected fellow of the American Institute for Medical and Biological Engineering, is a past Chairman for the Georgia Biomedical Partnership, a trade association, and is recipient of the 2004 Biomedical Industry Growth Award for the State of Georgia.

  • Russell Medford
    Managing Partner
    The Salutramed Group, Inc.

    Russell M. Medford, M.D., Ph.D. has served, since April 1, 2009, as Chairman and President of Salutria Pharmaceuticals, Inc., a biopharmaceutical company. From 1995 to April 1, 2009 Dr. Medford served as President, Chief Executive Officer and Director of AtheroGenics, Inc., a publicly-held pharmaceutical company.

    Dr. Medford serves on the Biotechnology Industry Organization Board of Directors and BIO Emerging Companies Section Governing Body, and he served as Chairman of the Georgia BioMedical Partnership from 2004 to 2007 and the Georgia Biotechnology Industry Organization Board of Directors. Dr. Medford was an Associate Professor of Medicine and Director of Molecular Cardiology at the Emory University School of Medicine, and currently holds the appointment of Adjunct Clinical Professor of Medicine. Dr. Medford received a B.A. from Cornell University, and a M.D. with Distinction and a Ph.D. in Molecular and Cell Biology from the Albert Einstein College of Medicine.

  • Gail Naughton
    CEO, Chairman of the Board
    Histogen, Inc.

    Dr. Naughton founded Histogen, Inc. in 2007, and currently serves as Chief Executive Officer and Chairman of the Board for the Company. She has spent more than 15 years extensively researching the tissue engineering process, holds more than 90 U.S. and foreign patents and has been extensively published in the field. In 2000, Dr. Naughton received the 27th Annual National Inventor of the Year award by the Intellectual Property Owners Association in honor of her pioneering work in the field of tissue engineering. While at San Diego State University, Dr. Naughton spearheaded a number of unique MBA programs in partnership with industry, played an instrumental role in the industry, research, and global accreditation committees of AACSB, and is a member of the Board of Directors of AACSB International. Dr. Naughton earned her Ph.D. and MS in Basic Medical Sciences from the New York University Medical Center and an executive MBA from the Anderson School at UCLA.

  • Stephen Padgette
    Vice President, R&D Investment Strategy
    Distinguished Science Fellow
    Monsanto Company

    Steve Padgette is currently the Vice President for Biotechnology in the Technology Sector of Monsanto Company, with responsibility for the worldwide discovery and development of plant biotechnology products. 
     
    After obtaining his B.S. and Ph.D. in Chemistry from the Georgia Institute of Technology, Steve joined Monsanto in 1984, focusing on the development of enzymes and genes to confer glyphosate tolerance to crop plants. Steve is co-inventor of Roundup Ready® technology, the most widely-used crop biotechnology trait in history. He assumed technical project responsibility for glyphosate-tolerant soybean, canola, and cotton in 1989, and led the regulatory science safety studies for these products starting in 1991. Following several years of research in plant metabolic engineering and co-leadership of the Soybean Business Team, he assumed his current role in 1998.  During Steve’s tenure, Monsanto Biotechnology has strengthened its industry-leading position in the discovery and development of crop biotechnology traits. Steve also has responsibility for Monsanto’s external collaboration and alliance strategy for biotechnology and genomics. Steve received his MBA from the Kellogg School of Management of Northwestern University in 2007.
     
    Steve is a member of the Board of Directors of Mendel Biotechnology. He serves as a member of the External Advisory Board, Georgia Institute of Technology, Institute for Bioengineering and Bioscience, is a member of the Technological Innovation: Generating Economic Results (TI:GER) Advisory Board, Georgia Institute of Technology College of Management, and is a member of The Department of Energy's Biological and Environmental Research Advisory Committee. He served on the St. Louis Science Center Board of Trustees and is currently serving as a member of its Science and Leadership Committee.  Steve is also a Monsanto Distinguished Science Fellow. Steve and his family reside in St. Louis, Missouri.

  • Pete Petit
    Chairman and CEO
    MiMedx Group, Inc.

    Pete Petit is a successful entrepreneurial executive who has also managed several public companies as Chairman and CEO. Therefore, his experience and perspectives are brought to the Petit Group’s investments.

    Pete Petit joined the MiMedx Group, Inc. as Chairman of the Board of Directors, Chief Executive Officer and President in February 2009. From May 2008 until he joined the Company, Mr. Petit was the President of The Petit Group, LLC, a private investment company. Prior to that, Mr. Petit was the Chairman and CEO of Matria Healthcare, Inc.,

    Matria Healthcare was a former subsidiary of Healthdyne, Inc., which Mr. Petit founded in 1971. Mr. Petit served as Chairman and CEO of Healthdyne and some of its publicly traded subsidiaries after Healthdyne became a publicly traded company in 1981. Mr. Petit received his bachelor?s degree in Mechanical Engineering and Master of Science degree in Engineering Mechanics from Georgia Tech and an MBA degree in Finance from Georgia State University. At Georgia Tech, Mr. Petit funded a professorial chair for ?Engineering in Medicine?, endowed the Petit Institute for Bioengineering and Bioscience, and assisted with the funding of the Biotechnology Building which bears his name. At Georgia State University, he assisted with the funding of the Science Center building which also bears his name. In 1994, he was inducted into the Technology Hall of Fame of Georgia. In 2007, he was inducted into the Georgia State Business Hall of Fame. Mr. Petit has previously served as a member of the Board of Directors of the Georgia Research Alliance, which is chartered by the State of Georgia to promote high technology and scientific development in the State

    Mr. Petit fully understands the entrepreneurial spirit and the associated trials and tribulations of growing businesses. The Petit Group seeks investment relationships in private corporations where its management and business expertise may be utilized in addition to its financial resources.

  • Brock Reeve
    Executive Director
    Harvard Stem Cell Institute

    Brock Reeve is Executive Director of the Harvard Stem Cell Institute. In partnership with the Faculty Directors, he has overall responsibility for the operations and strategy of the Institute whose mission is to use stem cells, both as tools and as therapies, to understand and treat the root causes of leading degenerative diseases.

    HSCI is comprised of the schools of Harvard University and all its affiliated hospitals and research institutions. Under the leadership of the Executive Committee, HSCI invests in scientific research and its faculty has grown to include over 300 Principal and Affiliated members. The Institute is engaged with several leading pharmaceutical companies and foundations in joint research projects and its faculty have founded several stem cell-related startup companies and serve on leading Scientific Advisory Boards.

    Brock came to this role from the commercial sector with extensive experience in both management consulting and operations for technology-based companies, with a focus on life sciences. Brock received a BA and MPhil from Yale University and an MBA from Harvard Business School.

  • Fred Sanfilippo
    Director, Healthcare Innovation Program
    Emory University

    Sanfilippo received his BA and MSc in physics from the University of Pennsylvania, and his MD and PhD from Duke University, where he also did his residency training and joined the faculty from 1979-1992, rising to professor of Pathology, Immunology, and Experimental Surgery.

    From 1993-2000, Dr. Sanfilippo was the Baxley Professor and Chair of the Department of Pathology at Johns Hopkins, and led the formation of the Johns Hopkins Comprehensive Transplant Center, for which he was the director of research. In 2000 he joined Ohio State University as CEO of the Medical Center, Senior VP for Health Sciences, and Dean of the College of Medicine and Public Health. With over 280 publications and $20 million in personal research grant support, he has received numerous awards and recognition for his research and leadership in transplantation, pathology, and academic medicine, has served on the editorial board of 13 professional journals, and been elected president of seven academic and professional organizations.

  • William Taylor
    President and COO
    MiMedx Group, Inc.

    Mr. Taylor has spent over 20 years in healthcare product design, development and manufacturing, and is currently the President and Chief Operating Officer of MiMedx Group, Inc., a small public company with three innovative biomaterial platform technologies focused on soft tissue repair. From 2001 through 2006, Mr. Taylor was President of Facet Technologies, LLC, a Matria Healthcare subsidiary and from 2006 to 2008, he led Facet as the CEO after it was sold to a private equity company. Facet is a medical device company focused on medical device design, development, and manufacturing for OEM clients such as Abbott, Bayer, BD, LifeScan (J&J), Roche, and Flextronics. Over his 14 year career at Facet and its predecessor company, he held various management positions, beginning with R&D, QA & Regulatory Affairs and progressing through General Management. Mr. Taylor was instrumental in growing the design and manufacturing business from $14 million in revenue up to over $40 million, when the company was sold to Matria Healthcare. As President, he led the company to the number one market position in Microsampling and grew it to over $85 million in revenue. A graduate of Purdue University, Mr. Taylor holds a Bachelor of Science degree in Mechanical Engineering and is co-inventor on eight patents.